http://www.ariva.de/news/...nts-as-an-Alternative-to-Daraprim-5529384 GrB  

ISIN: US45323A2015 Symbol: IMMYTyp: Aktie Aufnehmen in Watchlist/Depot
Imprimis Pharmaceuticals Announces New Economic Study Demonstrating $8.7 Billion in Potential Cost Savings over the Next 10 Years with the Adoption of Dropless Therapy™ http://www.ariva.de/news/...-the-Adoption-of-Dropless-Therapy-5532653  

-- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, announced that it has commenced construction on the company's Allen, Texas compounding pharmacy and plans to register the pharmacy with the U.S. Food and Drug Administration (FDA) as a 503B sterile outsourcing facility under the Drug Quality and Security Act (DQSA) of 2013.  The DQSA was signed into law by President Obama on November 27, 2013 and created a new pathway, in which a compounding pharmacy can register with the FDA as an outsourcing facility. http://www.ariva.de/news/...he-FDA-as-an-Outsourcing-Facility-5537456
 

http://www.ariva.de/news/...-Full-Year-2015-Financial-Results-5670033 GrB  

-- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the 28th Annual ROTH conference on Wednesday, March 16, 2016 at 12:30 p.m. (PDT) at Dana Point, Calif.  The presentation will be broadcast in a live webcast and an archive of the webcast will be available for 90 days following the event.  Access will be available at wsw.com/webcast/roth30/immy or on the Investor Relations section of Imprimis' website at www.ImprimisPharma.com.  An updated investor presentation is now available and can be viewed at http://imprimispharma.investorroom.com/corporate-presentations.  Imprimis will also be hosting one-on-one meetings and attendees can contact their ROTH representative to arrange a meeting. http://www.ariva.de/news/...-ROTH-Conference-on-March-16-2016-5671589  

http://www.ariva.de/news/...ults-and-Provides-Business-Update-5693465 GrB  

Quarter 2016 Financial Report Conference Call and Webcast on August 15, 2016 at 4:30 p.m. EDT
Montag, 01.08.2016 15:05 von PR Newswire  http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472  

SAN DIEGO, August 1, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, today reported it will release second quarter 2016 financial results after the close of trading on Monday, August 15,  2016.  The company will host a conference call at 4:30 p.m. EDT/1:30 p.m. PDT on the same day to discuss the financial results and recent business developments. http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472  

please dial (877)-407-8035 for domestic callers or (201)-689-8035 for international callers.  To listen to the webcast, please visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A replay of the call will be available until September 15, 2016.  To access the replay, dial (877)-660-6853 domestically or (201)-612-7415 internationally and reference Conference ID: 13641964.     http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472

 

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model.  The company is focused on patient outcomes and affordability and offers high quality lower-cost custom compounded drugs in all 50 states.  Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.  http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472

buran und MfG

 

Registered Direct Offering
Mittwoch, 22.03.2017 13:05 von PR Newswire  http://www.ariva.de/news/...o-raise-3-1-million-in-registered-6080431  

Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer and Director
Freitag, 23.06.2017 14:00 von PR Newswire http://www.ariva.de/news/...s-sean-brynjelsen-chief-executive-6294371  

Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release third quarter 2017 financial r... http://irdirect.net/IMMY/...e=pr_immy&pagination=1&per_page=5  

http://www.imprimisrx.com/about-us/company-overview/

Hier übrigens die News zum Anstieg.

https://seekingalpha.com/news/...hortage-list-shares-ahead-51-percent  

http://www.nasdaq.com/de/symbol/immy/real-time  

https://m.benzinga.com/article/...%2Fimprimis-pharmaceuticals-inc.htm  

 

 

 

wo ist das realistische KZ, wer hat den Wert im Depot?  

Soll ab 25 profitabel werden.  

https://de.marketscreener.com/kurs/aktie/HARROW-INC-50060993/

https://www.harrow.com/about.html#history

https://finviz.com/quote.ashx?t=HROW&ty=c&ta=1&p=d  

https://www.finanzen.net/schaetzungen/harrow

https://de.marketscreener.com/kurs/aktie/HARROW-INC-50060993/finanzen/

https://finviz.com/quote.ashx?t=HROW&p=d

https://stocktwits.com/symbol/HROW

https://stocktwits.com/Finnish_boy/message/589469026